Ascendis Pharma A/SASNDNASDAQ
Loading
Year-over-year operating income growth rate
Percentile
P41
Within normal range
vs 2Y Ago
-0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -10.86% |
| Q3 2025 | 120.77% |
| Q2 2025 | 49.19% |
| Q1 2025 | -27309.40% |
| Q4 2024 | 100.40% |
| Q3 2024 | 27.40% |
| Q2 2024 | -171.15% |
| Q1 2024 | -34.24% |
| Q4 2023 | 72.76% |
| Q3 2023 | 4.57% |
| Q2 2023 | 1.98% |
| Q1 2023 | 2.51% |
| Q4 2022 | -1.99% |
| Q3 2022 | -1.84% |
| Q2 2022 | -10.83% |
| Q1 2022 | -13.72% |
| Q4 2021 | -16.14% |
| Q3 2021 | 17.60% |
| Q2 2021 | 5.63% |
| Q1 2021 | -30.33% |
| Q4 2020 | -21.34% |
| Q3 2020 | 4.97% |
| Q2 2020 | -13.31% |
| Q1 2020 | -12.89% |
| Q4 2019 | -20.06% |
| Q3 2019 | -4.73% |
| Q2 2019 | 8.36% |
| Q1 2019 | -56.98% |
| Q4 2018 | 6.36% |
| Q3 2018 | 15.75% |
| Q2 2018 | -29.19% |
| Q1 2018 | -10.47% |
| Q4 2017 | -1.17% |
| Q3 2017 | -27.59% |
| Q2 2017 | -4.69% |
| Q1 2017 | -5.97% |
| Q4 2016 | -23.65% |
| Q3 2016 | -21.40% |
| Q2 2016 | 17.21% |
| Q1 2016 | -27.73% |